Tag: Muscarinic agonists

It's a fact that most contraindications for muscarinic agonists are predictable consequences of their pharmacological effects on the body. Understanding what are the contraindications for muscarinic agonists is crucial for clinicians to avoid severe adverse reactions in vulnerable patients by carefully assessing their medical history.

The parasympathetic nervous system (PNS) is responsible for the body's 'rest and digest' functions, and parasympathomimetics are a class of medications that activate this system by mimicking the effects of the primary neurotransmitter, acetylcholine. Understanding what are the effects of parasympathomimetics is crucial for healthcare professionals and patients alike, as these drugs are used to treat a variety of conditions, from glaucoma to urinary retention.

In September 2024, the FDA approved Cobenfy for the treatment of schizophrenia, representing the first novel-mechanism drug for this condition in decades. As a new option becomes available, the question arises: **is Cobenfy better than Abilify** for patients seeking symptom relief?

According to clinical studies, diarrhea is a commonly reported side effect of oral pilocarpine, particularly in older patients, occurring in a small but significant percentage of users. This gastrointestinal disturbance is directly linked to the drug's mechanism of action, and understanding the cause is key to effective management.

For the first time in decades, a new class of antipsychotic medication was approved by the FDA in September 2024. This groundbreaking drug, Cobenfy (formerly known as KarXT), offers a novel mechanism of action, presenting a new therapeutic option for adults with schizophrenia.